Sun Pharmaceutical Industries got approval for its psoriasis drug Ilumya, a part of its specialty products portfolio, for the Japan market. This would strengthen Sun Pharma's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late.
It is the first innovative drug that Sun would launch in Japan. The approval was expected earlier by analysts.
Sun Pharma's stock reacted positively to the news, ending the day at Rs 481.8 on BSE, up marginally.
On Monday the company said that one of its wholly-owned subsidiaries got approval from Ministry of Health, Labour and Welfare (MHLW), Japan for